Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

GE Healthcare to acquire Xcellerex Inc.

Published: Thursday, March 08, 2012
Last Updated: Thursday, March 08, 2012
Bookmark and Share
Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market.

GE Healthcare, a unit of GE announced today it has reached an agreement to acquire Xcellerex, Inc. a supplier of innovative manufacturing technologies for the fast-growing biopharmaceutical industry.  The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.  The strong strategic fit between the two companies, combined with expanded capabilities in product development and marketing, will offer significant customer benefits.  Financial terms were not disclosed.

Xcellerex develops and produces turn-key biomanufacturing systems and production-scale bioreactors based around single-use components.   The proprietary products offer significant advantages such as faster installation, lower capital investment, reduced risk of cross-contamination, and significantly increased flexibility compared with traditional manufacturing technologies.  Xcellerex’s production-scale single-use bioreactor systems are complementary to GE Healthcare’s products and range of media for cell culture.  Xcellerex’s FlexFactory® is a complete custom-designed modular production platform based around single-use technologies that helps customers deploy manufacturing capacity more quickly.   Combining the expertise and capabilities of the two companies will enable GE Healthcare to offer a substantially wider range of added-value, integrated products and services to the biopharmaceutical industry.

Dr. Nigel Darby, Vice President of BioTechnologies, and Chief Technology Officer, GE Healthcare Life Sciences said, “GE Healthcare has built a world-class set of tools, technologies and services for the biopharmaceutical manufacturing industry, and by adding Xcellerex’s innovative products to our portfolio, we will be able to strongly enhance our customer offering.  GE and Xcellerex share the vision that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to increase production flexibility and to deliver higher yields of finished product while reducing time to market.  With the global focus on spiralling health costs and the need for sustainable healthcare, these are critical issues for the industry.”

Welcoming the acquisition, Guy Broadbent, President and CEO of Xcellerex, said, "We are very excited to become part of GE Healthcare’s Life Sciences business.  The combination of Xcellerex’s people, technologies and services with the resources and global reach of GE Healthcare will allow us to bring forward our plans to grow the business.  The integration of Xcellerex’s products with GE Healthcare’s complementary capabilities in upstream and downstream bioprocessing will help bring great benefits to our customers.  The entire Xcellerex team looks forward to joining GE.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals
Companies to help emerging nations develop their own manufacturing capabilities for essential biopharmaceuticals, reducing reliance on imports.
Wednesday, December 14, 2011
The Inaugural Winner of GE Healthcare High-Content Analysis (HCA) Award Achieved 20-Fold Increase in Throughput
The inaugural winner of the first GE Healthcare HCA Award has been announced. Supported by BioTechniques, the Award recognizes the outstanding contribution of HCA to scientific understanding and celebrates its positive impact on data quality and quantity, resulting in increased productivity, deeper insights and better decisions.
Friday, October 29, 2010
Scientific News
Antibiotic Overuse Might be Why so Many People Have Allergies
The Centers for Disease Control and Prevention estimates that drug resistant bacteria cause 23,000 deaths and two million illnesses each year.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.
What Do Animal Viruses Have to Do with Human Health?
Simon Anthony studies animal infections to prevent outbreaks in people.
‘Immune Camouflage’ may Explain H7N9 Influenza Vaccine Failure
The study is published in Human Vaccines & Immunotherapeutics.
How Flu Viruses Gain The Ability To Spread
New study reveals the soft palate is a key site for evolution of airborne transmissibility.
New Cell Type May Help Explain Dangerous Food Allergies
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Scientists Create Immunity to Deadly Parasite by Manipulating Host’s Genes
Research suggests a novel approach to boosting immunity by removing the mechanism that allows pathogens to cause disease.
10 to 1: Bugs Win in NASA study
Bugs are winning out, and that's a good thing according to NASA's Human Research Program.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos